Takeaway
- Prophylactic use of aspirin may delay development of preterm and term preeclampsia.
- Women with risk factors for preeclampsia may experience greater benefits.
Why this matters
- The mechanism for how aspirin prevents preeclampsia is unclear.
Key results
- The experimental model proves aspirin prevents both preterm and term preeclampsia, but high-risk patients differed from low-risk patients.
- In high-risk patients, the risk for preterm preeclampsia was reduced in women on aspirin (2.7% vs 7.1%).
- In low-risk patients, the use of prophylactic aspirin reduced the risk for term preeclampsia (3.6% vs 5.7%).
Study design
- Unplanned secondary subgroup analysis of data from the ASPRE trial, involving 13 hospitals investigating risks for and prevention of preeclampsia with aspirin.
- A model was developed and fitted to examine the hypothesis that aspirin causes a delay in gestational age at time of diagnosis of preeclampsia.
- Funding: Fetal Medicine Foundation and European Union 7th Framework Programme.
Limitations
- Model needs to be validated.
- Lack of power for preeclampsia at term.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionalsLogin to
account
Don’t have an account? Get started